Author Archives: admin


Stem Cell Clinic > Articles by: admin

Stem Cell Therapy Market Statistics, Trends, Size, Growth Opportunities, Share Demand and Forecast to 2025 – Jewish Life News

By Stem Cell Doctors

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Here is the original post:
Stem Cell Therapy Market Statistics, Trends, Size, Growth Opportunities, Share Demand and Forecast to 2025 - Jewish Life News

Why this Island woman is giving part of her liver to a complete stranger – Yahoo News Canada

By Stem Cell Doctors

Trina Doyle describes herself as many things.She's a mom, a daughter, a dog-lover, and pretty soon, she'll be adding organ donor to that list.

For the last 10months, Doyle has been preparing to donate part of her liver to someone in needand that person is a complete stranger.

The single mom of two from Tignish, P.E.I., will soon be travelling to Toronto General Hospital, where she will donate a portion of her liver through the University Health Network'sliving organ donor program.

Heranonymous donation meansDoyle may never meet the person who receives her liver, but she said thatnever factored into her decision to donate.

I just feel like it's what I need to do knowing that I can help, I just really want to. Trina Doyle

"It's not about finding out who it is, it's just about helping them," Doyle said.

"This person has probably been living with illness for quite a while in order to be on the transplant list and going through a lot. So the little bit that I do is small compared to what they have to go through."

Always wanted to be a donor

Doyle said the decision to become a donor began when she was a teenager and found out a child in her community needed a bone marrow transplant.

"The information they gave me at the time brought things into perspective that you know, these people need this help," Doyle said.

Though she wasn't a match in that case, Doyle said she was inspired to find other ways to help people in need. When she moved to Saint John to attend universityshe started donating blood giving as often as she could and signed up to become a stem-cell donor.

"In the last couple years somebody had posted something on Facebook about donating organs and I thought, 'Oh I don't think I'm on that registry so I should sign up,'" Doyle said.

Shesubmitted her application to become a livingdonorjust before Christmas in 2018. The following spring she startedtesting to find out if she was eligible to donate.

Months of testing

Doyle began doing tests with her family doctor on P.E.I. and soon started travelling to Moncton, N.B., for more specific testing before heading to Toronto for the final round of exams.

Dr. Nazia Selzner is the medical director of the Live Donor Liver Program at theSoham and Shaila Ajmera Family Transplant Centre with the University Health Network.She said patient safety is the top concern andsteps are taken to ensure donors are physically and emotionally healthy enough to go through the surgery.

Submitted by Trina Doyle

Story continues

Selzner said tests includeMRIs and CT scans to look at liver health as well as tests to detect infections, and monitor heart and lung health.

The program also tries to make sure donors are ready for the surgery in other ways, she said, including psychiatric assessments, financial planning, surgical risk consultation and support during the recovery process.

Living donations reduce wait times

Selzner saidsince the program began in 2000, over 900 liver transplants from living donors have been performed and about 10 per cent of those donations came from anonymous donors.

At any given time there can be up to200 people on the wait-list to get a liver donation in Toronto alone, she said. This is often because patients are waiting for a deceased donor, which in some cases can take too long.

"For a deceased donor you have to wait until your turn comes," she said."There are always sicker patients that are added to the list so you never actually know when you can get a transplant and sometimes you may wait for years."

She said each year about 30 per cent of people in need of a transplant die waiting fora donor, including patients who may be very sick, but fail to meet the criteria to get a liver from a deceased donor.

Selzner said living organ donations helpreduce wait timesand, as a result, can improve the long-term outcome of having a transplant.

"Transplantation through a live donation means that the organ is retrieved from a healthy donor," she said. "So the quality of the organs are excellent."

She said the fact that the surgery is planned is also a benefit because it can be scheduled for a time when both donor and recipient are at their healthiest and doctors can better prepare for the procedure.

Selzner said most healthy peoplebetween the age of 16 and 60 could be eligible to donate. She saidjust a few weeks after surgery, the donor's liver will return to its original size.

"The liver has this beautiful ability to regenerate," she said. "The liver will grow back to full size in the donor, but also the piece that is transplanted into the recipient grows to full size."

Nerves turning into excitement

For Doyle, waiting for the call was the hardest part and now that she knows the program found a match, those nerves are starting to fade away.

She'll have to stay in the hospital for about a week after her surgery and then stay in Toronto for at least two more weeks so doctors can monitor her recovery.

Some family members are going with her and will be thereby her side.

"We're all very proud of her and it's an incredible thing,"said her sister Lorna Doyle-DesRoches.

"There's no lines of what you can do in life, it's just, there's no limits and she's definitely jumped on this and never thought twice."

"If anybody was going to do it, it would be her," said her father, Lorne Doyle.

Doyle-DesRoches saidthere's been an outpouring of support from the community, offering everything from cash donations to gift cards to help Doyle and her family while she's in Toronto. Others have approached her looking for information about how they can become donors themselves.

"It's bringing awareness to our whole community," shesaid.

'There's a lot of lives that can be saved'

After the surgery, Doyle said she's allowed to write a letter the recipient of her liver can one day read if they want to.

Otherwise, they may remain strangers forever.

But for Doyle, the most important part of this experience has been her chance to raise awareness about living organ donation and show others that if she can do it, maybe they can too.

"I'm really hoping that people become aware of the need that there is for living donors," Doyle said.

"If more people sign up and commit to doing these things then there's a lot of lives that can be saved."

As she gets closer to her surgery date, Doyle said there are some moments when she feelsafraid. But if overcoming those fears means she may save a life and even inspire someone else to try to do the same, she saidit will all be worth it.

"I just feel like it's what I need to do knowing that I can help, I just really want to."

More P.E.I. news

Read the rest here:
Why this Island woman is giving part of her liver to a complete stranger - Yahoo News Canada

The life and controversial career of radio host Rush Limbaugh – Business Insider – Business Insider

By Stem Cell Doctors

Rush Limbaugh may be the most incendiary radio host in America.

Born into a line of conservative lawyers, Limbaugh hated school and saw radio as his future.

At first, his radio career was tumultuous. He was fired more than once as he discovered what could and couldn't be said on air.

He first commanded a national audience at 37. In the 1990s, he became a political force. Every week, he spoke to millions of Americans. In 1994, he was credited for Republicans taking the majority in the House of Representatives, after campaigning vigorously on air.

According to Vanity Fair, Limbaugh's position with conservatives is comparable to Oprah's position with women they both wield "concentrated and extraordinary power."

But while Republicans have backed him and listened to him, he's despised by many liberals for mocking and attacking minorities.

In February, Limbaugh announced he had advanced lung cancer. In the same month, President Donald Trump awarded Limbaugh the Medal of Freedom, during his State of the Union address.

Here's his life so far.

Read this article:
The life and controversial career of radio host Rush Limbaugh - Business Insider - Business Insider

BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update – GlobeNewswire

By Stem Cell Medicine

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and full year ended December 31, 2019, and provide a corporate update, at 8:00 a.m., Eastern Time, on Tuesday, February 18, 2020.

BrainStorms President & CEO, Chaim Lebovits, will present the full year 2019 corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, and Preetam Shah, PhD, Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.comand questions should be submitted by 5:00 p.m., Eastern Time, Monday, February 17 2020.

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. Brainstorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. Brainstorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: 862-397-8160pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Here is the original post:
BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update - GlobeNewswire

Protecting growth-restricted babies from brain injury with stem cell therapy – Mirage News

By Stem Cell Treatment

Hudson Institute scientists have demonstrated for the first time that umbilical cord stem cells can protect preterm, growth-restricted babies from brain injury.

Up to five-eight percent of pregnancies in Australia are affected by fetal growth restriction (FGR)-a condition which leads to poor growth of an unborn baby.

The mechanical ventilation that these babies need for the first few days of life can have detrimental effects on the developing brain. Many of them are born early (also referred to as preterm or premature), which only exacerbates the risk of brain injury further.

This brain damage often causes long-term developmental problems, and can lead to conditions such as cerebral palsy, behavioural disorders, cognitive deficits and motor developmental delays.

There is currently no treatment which can be used as an early intervention to prevent brain damage of babies with FGR. However, a growing body of evidence suggests that stem cell therapies could be the answer to this problem.

Dr Atul Malhotra and Associate Professor Suzie Miller led a study published in Stem Cell Research and Therapy which investigated the effect of umbilical cord blood stem cells (UCBCs) in a preclinical model of FGR.

Dr Malhotra is a consultant neonatologist at Monash Newborn, Monash Childrens Hospital; a senior lecturer in the Department of Paediatrics, Monash University; and a research fellow at Hudson Institute. Associate Professor Miller is a Deputy Centre Head at Hudson Institute and a senior scientist at the Department of Obstetrics and Gynaecology, Monash University.

The team demonstrated, for the first time, that UCBCs can alleviate the brain damage caused by FGR and being born preterm-a ground-breaking discovery with significant implications for treatment.

Treatment with UCBCs led to a decrease in neuroinflammation, oxidative stress, cerebrovascular resistance (obstruction to blood flow), and greater integrity of the neurovascular unit in the brain.

The team believe that UCBCs stabilise the neurovascular unit-comprising of several different cell structures that control blood flow to the brain-possibly by reducing the inflammation surrounding them.

These UCBCs therefore act by strengthening the gate keepers of the brain, which in turn mitigates the effects of brain injury caused by an early and growth restricted birth.

We propose that the results of this study lay the foundation for a novel therapeutic option, using cord blood stem cells as an early intervention therapy for these vulnerable babies, commented Dr Malhotra.

Cell therapy is now ready for translation to clinical trials and this study provides further evidence of its potential benefit in preterm infants.

The teams next step is therefore a clinical trial of cord blood therapy in preterm babies at Monash Childrens Hospital, testing feasibility and safety of the treatment.

FGR is a condition where an unborn baby, or fetus, is smaller than expected

It can begin at any time during pregnancy, and puts babies at risk of loss in brain development, which can cause the child long-term problems in later life such as cerebral palsy, autism, learning and other behavioural challenges

Factors in the mother such as high blood pressure, diabetes, cigarette smoking and alcohol or drug use can increase the risk of FGR

The risk can also be increased by the placenta not attaching well, or blood flow through the umbilical cord being limited

Collaborators

Monash University.

Funders

National Health and Medical Research Council (NHMRC), Cerebral Palsy Alliance, The Royal Australasian College of Physicians.

Read more:
Protecting growth-restricted babies from brain injury with stem cell therapy - Mirage News

LifeGaines Medical and Aesthetics Provides Innovative Options for Age Management in Their Boca Raton Office – MENAFN.COM

By Stem Cell Treatment

(MENAFN - Newswire) BOCA RATON, Fla.,February 11, 2020(Newswire.com) - Focusing on age management and regenerative therapies, the team at LifeGaines Medical and Aesthetics is led by a highly respected pioneer in age management medicine, Dr. Richard Gaines . Board Certified by the American Board of Anti-Aging & Regenerative Medicine, Dr. Richard Gaines is qualified to provide advanced age managementprotocols to those who seek them. This enables LifeGaines to offer cutting-edge therapies in their Boca Raton office .

As a certified Functional Medicine Practitioner, Dr. Gaines believes in using an integrative approach to achieve total body health. He and his team do this by offering several different treatments to their clients that are said to help people who are aging keep their health throughout their golden years. Among these treatments are hormone replacement therapy, stem cell therapy and joint injections. Get age management treatments from a trusted Boca Ratonphysician at LifeGaines Medical and Aesthetics.

Age management looks different for every person that visits LifeGaines Medical and Aesthetics . Some people are looking for help in maintaining their sexual wellness while others are more concerned with cosmetic changes like sunspots and unsightly veins. The team at LifeGaines understands that overall well-being is about both controlling the physiological changes as well as the cosmetic changes. To best serve their clients, LifeGaines Medical and Aesthetics also offers aesthetic procedures in their age management programs. The most common of these procedures are PRP facials, sun spot removal, Botox, and spider vein removal. Access advanced age management practices by calling LifeGaines Medical and Aesthetics at (561) 931-2430.

In addition to their wellness therapies and cosmetic procedures, Dr. Richard Gaines also helps those suffering from sexual dysfunction due to aging. Without the use of commonly prescribed pharmaceuticals, Dr. Gaines and the team at LifeGaines use hormone therapy to help their clients maintain their sexual wellness and boost their libido. As a piece of overall health, sexual wellness is a significant part of age management medicine.

LifeGaines Medical and Aesthetics is an age management practice owned by renowned functional medicine practitioner, Dr. Richard Gaines. His age management practice provides a wide selection ofcosmetic treatments from their office located atFlorida. The team at LifeGaines specializes in age management treatments, stem cell therapy, sexual wellness and platelet-rich plasma procedures. With the services offered at LifeGaines Medical and Aesthetics, South Floridians can maintain their overall health and improve their quality of life as they age. Aging Floridiansshould visit LifeGaines Medical and Aesthetics online or call their office at 3785 N. Federal Highway in BocaRaton to schedule their initial consultation.

MENAFN1102202000704191ID1099689481

Visit link:
LifeGaines Medical and Aesthetics Provides Innovative Options for Age Management in Their Boca Raton Office - MENAFN.COM

Inflammasome Pathway Linked to MS and Diseases of Aging Has an… – Multiple Sclerosis News Today

By Stem Cell Treatment

Immune cells have an inflammation switch that involves the NLRP3 inflammasome pathway, and targeting it may prevent or even reverse the chronic inflammation seen in diseases like multiple sclerosis (MS) and in conditions associated with aging, an early study suggests.

The inflammation marking MS has been linked to NLRP3 inflammasome activation.

The study, An Acetylation Switch of the NLRP3 Inflammasome Regulates Aging-Associated Chronic Inflammation and Insulin Resistance, was published in the journal Cell Metabolism.

Chronic inflammation, which results from an overactive immune response, can intensify with age and lead to a variety of illnesses, fromAlzheimersand MS to cancer and diabetes.

The molecular triggers responsible for provoking the immune system, however, are not clear.

A team led by researchers at the University of California (UC), Berkeley, discovered a molecular switch that controls chronic inflammation in the body.

Using models of older mice, the scientists developed a cell-based system that models aging-associated inflammation. It simulates the effects of inflammation over metabolism including for insulin resistance, a pre-diabetic condition marked by cells that no longer respond well to insulin.

My lab is very interested in understanding the reversibility of aging, Danica Chen, professor at UC Berkeley, and the studys senior author, said in a news story.

In the past, we showed that aged stem cells [progenitor cells with the potential to develop into several cell types] can be rejuvenated. Now, we are asking: to what extent can aging be reversed?

And we are doing that by looking at physiological conditions, like inflammation and insulin resistance, that have been associated with aging-related degeneration and diseases, Chen added.

Using their models, the team showed that a pathway wired to immune cells, called theNLRP3 inflammasome, is at the origin of aging-associated inflammation. Importantly, the researchers found a potential way to switch it off.

This inflammasome consists of a sensor molecule, called NLRP3, that senses threats or danger signals inside immune cells, to rapidly recruit other proteins and launch an inflammatory response. Such a pathway is central to coordinating proinflammatory responses, and has been implicated in chronic conditions like MS, cancer, and diabetes.

Research in MS patients suggests that inflammasome activation occurs during disease. Experiments in MS mouse models also support the NLRP3 inflammasome as critical and necessary to MS development.

Working with mice and immune cells called macrophages, Chen and his colleagues discovered that a specific chemical modification called acetylation (the addition of an acetyl group to a compound) works as a molecular switch that turns on this inflammasome.

When NLRP3 is acetylated, it stays in a more active form that favors inflammation, they reported. However, this active state can be prevented by a protein called SIRT2 that takes out the acetyl (essentially, deacetylates NLRP3), shutting off the inflammasome.

Mice genetically engineered to lack SIRT2 showed more signs of inflammation at an older age than did their normal counterparts. These mice also exhibited higher insulin resistance, a condition associated with type 2 diabetes and metabolic syndrome.

This acetylation can serve as a switch, Chen said. So, when it is acetylated, this inflammasome is on. When it is deacetylated, the inflammasome is off.

This finding suggests that treatments that deacetylate switch off the NLRP3 inflammasome might help to prevent or treat conditions related to aging and inflammation, and perhaps age-related degeneration in general.

Studying older mice that produced either the deacetylated or the acetylated version of NLRP3, the team saw that those with the deacetylated, or off, version of the inflammasome had better insulin resistance after six weeks.

This suggests that targeting NLRP3 acetylation might actually reverse inflammatory conditions.

These results establish the dysregulation of the acetylation switch of the NLRP3 inflammasome as an origin of aging-associated chronic inflammation, and highlight the reversibility of aging-associated chronic inflammation and insulin resistance, researchers wrote.

I think this finding has very important implications in treating major human chronic diseases, Chen said.I think its more urgent than ever to understand the reversibility of aging-related conditions, and use that knowledge to aid a drug development for aging-related diseases.

Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.

Total Posts: 1,053

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Read this article:
Inflammasome Pathway Linked to MS and Diseases of Aging Has an... - Multiple Sclerosis News Today

BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn Regulatory Pathway for Approval in ALS – Yahoo Finance

By Adult Stem Cells

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company recently held a high level meeting with the U.S. Food and Drug Administration (FDA) to discuss potential NurOwn regulatory pathways for approval in ALS. Repeated intrathecal administration of NurOwn (autologous MSC-NTF cells) is currently being evaluated in a fully enrolled Phase 3 pivotal trial in ALS (NCT03280056).

In the planned meeting with senior Center for Biologics Evaluation and Research (CBER) leadership and several leading U.S. ALS experts, the FDA confirmed that the fully enrolled Phase 3 ALS trial is collecting relevant data critical to the assessment of NurOwn efficacy. The FDA indicated that they will look at the "totality of the evidence" in the expected Phase 3 clinical trial data. Furthermore, based on their detailed data assessment, they are committed to work collaboratively with BrainStorm to identify a regulatory pathway forward, including opportunities to expedite statistical review of data from the Phase 3 trial.

Both the FDA and BrainStorm acknowledged the urgent unmet need and the shared goal of moving much needed therapies for ALS forward as quickly as possible.

This is a key turning point in ourworktowardprovidingALSpatientswith a potential new therapy,said ChaimLebovits, President and CEO ofBrainStorm. We commend the FDA foritscommitmentto the ALS communityandtofacilitating the development, and we ultimately hope, the approvalofNurOwn.The entire BrainStorm team is grateful for the ongoing and conscientious collaboration in the quest to beat ALS.

Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, stated, The entire team at BrainStorm has collectively worked to ensure that we conduct the finest, science-based clinical trials. We had the opportunity to communicate with Senior Leadership at the FDA and discuss how we can work together to navigate the approval process forward along a novel pathway. We appreciate their willingness and receptiveness to consider innovative approaches as we all seek to better serve the urgent unmet medical needs of the ALS community.

Brian Wallach, Co-Founder of I AM ALS stated: There is nothing more important to those living with ALS than having access to therapies that effectively combat this fatal disease. We have been working with BrainStorm for months now because we believe that NurOwn is a potentially transformative therapy in this fight. We were privileged to represent the patient voice at this meeting and are truly grateful to the company and the FDA for this critical agreement. This is a truly important moment of hope and we look forward to seeing both the Phase III data and the hopeful approval of NurOwn as soon as is possible.

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. BrainStorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Or

Katie Gallagher | Account Director, PR and MarketingLaVoieHealthScience Strategic CommunicationsO: 617-374-8800 x109M: 617-792-3937kgallagher@lavoiehealthscience.com

More here:
BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn Regulatory Pathway for Approval in ALS - Yahoo Finance

Astrocytes could be harnessed to protect motor neurons in MND – Drug Target Review

By Adult Stem Cells

Scientists using a new motor neuron disease (MND) model have shown astrocytes may protect neurons from toxic TDP-43 protein aggregates in the early stages of disease.

Researchers have discovered that astrocytes can protect motor neurons in the central nervous system (CNS) from the toxicity of misfolded protein, TDP-43, in sporadic motor neuron disease (MND). The team suggest this rescue mechanism could be harnessed to slow disease progression, particularly in amyotrophic lateral sclerosis (ALS).

The study, published in Brain, demonstrated that this neurodegenerative disease is caused by accumulation of TDP-43 in motor neurons, resulting in cell death. However, the scientists noted that TDP-43 accumulation in neural support cells, called astrocytes, does not cause death. Instead they appear comparatively resistant.

According to the paper, when the two cell types are together, astrocytes protect motor neurons from the protein aggregates, promoting their survival. The researchers from the Francis Crick Institute and University College London, both UK, suggest that these cells may therefore be supporting motor neurons early on in sporadic MND. They called this a rescue mechanism.

when the two cell types are together, astrocytes protect motor neurons from the protein aggregates, promoting their survival

The role astrocytes have played in dealing with toxic forms of TDP-43 in motor neurons has not been previously well documented in motor neuron disease. Its exciting that weve now found that they may play an important protective role in the early-stages of this disease, explains Phillip Smethurst, lead author and former postdoc in the Human Stem Cells and Neurodegeneration Laboratory at the Crick. This has huge therapeutic potential finding ways to harness the protective properties of astrocytes could pave the way to new treatments. This could prolong their rescue function or find a way to mimic their behaviour in motor neurons so that they can protect themselves from the toxic protein.

In order to conduct this research, the team created a new model for MND, which more closely resembles the disease in patients. In the model they took healthy adult stem cells and exposed them to the toxic TPD-43 protein using post-mortem spinal cord tissue samples donated by patients with MND.

For the first time, we have been able to create a model of sporadic motor neuron disease by essentially transferring the toxic TDP-43 protein from post-mortem tissue into healthy human stem cell-derived motor neurons and astrocytes in order to understand how each cell type responds to this insult, both in isolation and when mixed together, said Dr Rickie Patani, co-senior author, group leader of the Human Stem Cells and Neurodegeneration Laboratory at the Crick and Professor of Human Stem Cells and Regenerative Neurology at UCL Queen Square Institute of Neurology.

Read the rest here:
Astrocytes could be harnessed to protect motor neurons in MND - Drug Target Review

Mexico City Medical Congress to Showcase the Global Stem Cells Group’s Latest Innovations – PRUnderground

By Adult Stem Cells

The Global Stem Cells Group (GSCG) is set to sponsor the XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad (World Conference of Anti-Aging and Longevity Medicine) to be held in Mexico City, Mexico on February 16-18, 2020.

The medical congress is expected to attract over 450 physicians and researchers from across the world interested in anti-aging and longevity practices and medical innovations. Over 30 speakers are slated to share information with attendees on a wide range of topics on how to lead a long, healthy life and improve longevity.

The GSCG is set to share a number of its latest innovations with congress attendees, including its newly released GCell technology device. This cutting-edge tool utilizes micrograft technology to harness the natural and powerful restorative capabilities of adipose tissues. Because it is FDA compliant, the device allows physicians across the globe to continue practicing adult stem cells-based procedures.

Additional benefits of GCell technology include shorter treatment times, delivering in-office treatments in around 30 minutes with local anesthesia, as well as less fat collection compared to existing treatments (15 mL versus 50 mL). GCell technology holds exciting implications across a range of medical specialties, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.

In addition to its GCell technology, the GSCG will also feature its newest line of stem cells products derived from first-tissue exosomes. Cellgenic Flow Exosomes utilizes the latest science and research available in cellular therapies to deliver a non-surgical approach to creating regenerative responses in a broad range of treatments. The product utilizes exosomes, which replicate the signals given out by stem cells, versus actual stem cells. Exosomes play a pivotal role in cell-to-cell communication and are involved in a wide range of physiological processes. These particles transfer critical bioactive molecules such as proteins, mRNA, and miRNA between cells and regulate gene expression in recipient cells.

The XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad is one of the worlds premier events connecting physicians and researchers with todays most innovative treatments and technologies utilizing regenerative medicine, said Benito Novas, CEO of the GSCG. As a worldwide leader in training, education, and innovative products in the field of regenerative medicine, the GSCG is pleased to sponsor this congress and share its exciting new portfolio of products with physicians from across the world.

To learn more about the Global Stem Cells Group and all of the groups latest news and innovations, visit http://www.stemcellsgroup.com/

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCGs affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Read the original here:
Mexico City Medical Congress to Showcase the Global Stem Cells Group's Latest Innovations - PRUnderground

→←